Opening Comments at the American Association for the Advancement of Science (AAAS) consultation on Human Enhancement
By Richard Hayes
| 06. 01. 2006
Mark Frankel asked if we’d share some general perspectives on what we believe to be the major challenges posed as we consider technologies of “enhancement.” I’d like to share the perspective of the Center for Genetics and Society, as well as what we’ve learned about the perspectives of a wide range of Americans and others.
CGS got started following a series of meetings held in 2000 on the social and political implications of the new human genetic technologies. The meetings brought together people concerned about social and economic justice, women’s health and reproductive rights, science and society, environmental protection, and the rights of the disabled.
Those participating became concerned when they learned how rapidly these new technologies were being developed, how profoundly consequential these could be, how thin were the few rules and regulations in place, and how well below the radar screens of both the general public and policy makers all this was.
A major concern was that use of these technologies could greatly exacerbate human inequality, in particular through a revival of eugenic technologies and ideologies, this time...
Related Articles
By Emily Mullin, Wired | 11.14.2023
In a small initial test in people, researchers have shown that a single infusion of a novel gene-editing treatment can reduce cholesterol, the fatty substance that clogs and hardens arteries over time.
The gene-editing treatment aims to permanently lower cholesterol...
By Carissa Wong, Nature | 11.16.2023
In a world first, the UK medicines regulator has approved a therapy that uses the CRISPR–Cas9 gene-editing tool as a treatment. The decision marks another high point for a biotechnology that has been lauded as revolutionary in the decade since...
By Emily Mullin, Wired | 11.16.2023
The first medical treatment that uses Crispr gene editing was authorized Thursday by the United Kingdom.
The one-time therapy, which will be sold under the brand name Casgevy, is for patients with sickle cell disease and a related blood disorder...
By Jocelyn Kaiser, Science | 11.12.2023
A technique for precisely rewriting the genetic code directly in the body has slashed “bad” cholesterol levels—possibly for life—in three people prone to dangerously high levels of the artery-clogging fat. The feat relied on a blood infusion of a so-called...